Trinovium to supply RTI with advanced fluids and analytical systems for deployment in a U.S. commercial pilot focused on AI and high-performance computing data center infrastructure Data center power densities are
- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues update on Nasdaq
- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular data center
– Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company’s business transformation – – Trinity Biotech
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), (the "Company") today announced that it plans to change the ratio of the American depositary shares ("ADSs") representing
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 20331 DUBLIN and
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets – Company publishes Q1 2026 financial results with revenue in line with prior guidance &
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation Plan -
Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK, March 23, 2026
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a
